These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 20527351)
1. [Quetiapine, an antipsychotic agent to consider in the differential diagnosis of convulsions]. Rodrigo Casanova MP; Castrillo Villamando S; García Peña JM; Aguilera Celorrio L Rev Esp Anestesiol Reanim; 2010 May; 57(5):320-1. PubMed ID: 20527351 [No Abstract] [Full Text] [Related]
2. A case of atypical antipsychotic-induced somnambulism: a class effect. Dagan Y; Katz G J Clin Psychiatry; 2013 Apr; 74(4):370. PubMed ID: 23656842 [No Abstract] [Full Text] [Related]
3. Severe hyperlipidemia associated with olanzapine and quetiapine use. Carnahan RM; Reantaso AA; Teegarden BA; Pogue T Am J Psychiatry; 2007 Oct; 164(10):1614-5. PubMed ID: 17898359 [No Abstract] [Full Text] [Related]
4. Restless legs syndrome associated with the combined use of quetiapine and venlafaxine. Michopoulos I; Ferentinos P; Oulis P; Gournellis R J Clin Psychopharmacol; 2014 Feb; 34(1):159-61. PubMed ID: 24135842 [No Abstract] [Full Text] [Related]
5. Quetiapine: a review of its use in the treatment of bipolar depression. Keating GM; Robinson DM Drugs; 2007; 67(7):1077-95. PubMed ID: 17488148 [TBL] [Abstract][Full Text] [Related]
6. Pros and cons of approved therapies for bipolar depression and ongoing unmet needs. McElroy SL J Clin Psychiatry; 2014 Oct; 75(10):e26. PubMed ID: 25373131 [TBL] [Abstract][Full Text] [Related]
7. Severe creatine kinase increase during quetiapine and mirtazapine treatment. Apikoglu Rabus S; Izzettin F; Rabus M; Bilici M Psychopharmacology (Berl); 2006 Apr; 185(2):263-4. PubMed ID: 16374598 [No Abstract] [Full Text] [Related]
8. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting. Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027 [TBL] [Abstract][Full Text] [Related]
9. Quetiapine: a review of its use in acute mania and depression associated with bipolar disorder. Dando TM; Keating GM Drugs; 2005; 65(17):2533-51. PubMed ID: 16296876 [TBL] [Abstract][Full Text] [Related]
10. Diabetes mellitus during olanzapine and quetiapine treatment in Japan. Cohen D J Clin Psychiatry; 2005 Feb; 66(2):265-6; author reply 266-7. PubMed ID: 15705015 [No Abstract] [Full Text] [Related]
11. An update on the treatment of bipolar depression. Azorin JM; Kaladjian A Expert Opin Pharmacother; 2009 Feb; 10(2):161-72. PubMed ID: 19236191 [TBL] [Abstract][Full Text] [Related]
12. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone. Jing Y; Kim E; You M; Pikalov A; Tran QV J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. Altamura AC; Salvadori D; Madaro D; Santini A; Mundo E J Affect Disord; 2003 Sep; 76(1-3):267-71. PubMed ID: 12943958 [TBL] [Abstract][Full Text] [Related]